NovaBay Pharmaceuticals aims to keep the "bed bugs" away. The clinical-stage biopharmaceutical company develops antimicrobial compounds (known as Aganocide compounds) for the treatment and prevention of infections in hospital and non-hospital environments. Aganocide compounds destroy bacteria by attacking multiple sites, and aim to treat and prevent bacterial, fungal, and viral infections. The compounds are intended to prevent infections resulting from surgical or other hospital procedures, such as nasal surgery, urinary tract catheterization, and wound care, as well as for use on patients with infections of the eyes, ears, sinuses, or skin.